21 Jan Ensoma
Posted at 20:58h
in
Jonathan Garen, Chief Corporate Development Officer
April 16 | 9:45am | Salone dei Cavalieri, Section 2
Boston, MA
(Private)
Ensoma is a in vivo HSC (hemopoietic stem cell) engineering company. We have programs in rare disease, sickle cell disease and solid tumor immuno-oncology. Our lead program is expected to enter the clinic by mid-2025. Our platform is unique able to safely insert large genes and edit genes in a single product, enable lineage cell specific expression and multiplexing, and enables control functions to accurately titrate up and down levels of modified HSC cells. Ensoma has a base editor that allows efficiently edits without any DNA cuts.
